查看文章

We describe the New Zealand Parkinson’s Progression Programme (NZP3), its goals, findings, and future plans. To date, 354 people with Parkinson’s disease and 89 healthy older controls have participated over a 14-year period. A major focus of the programme has been the characterisation of current cognitive impairment, and the identification of biomarkers for its future emergence in people with Parkinson’s. The programme has made significant contributions to the concept of mild cognitive impairment (MCI) in Parkinson’s and the development and validation of standardised criteria for it. Brain imaging, both MRI and PET, has also been a focus, showing associations between increasing brain pathology and declining cognitive function. Additional biomarkers such as genetics, fluid biomarkers, eye movement, speech, and quantitative electroencephalography (EEG) are also under investigation. The programme …